Related Experiment Videos
Heparin plus dipyridamole in childhood hemolytic-uremic syndrome: a prospective, randomized study
R Van Damme-Lombaerts1, W Proesmans, B Van Damme
1Department of Pediatrics, University of Leuven, Belgium.
Insights
This study found that heparin and dipyridamole offer no advantage over supportive care for children with hemolytic-uremic syndrome. The treatment did not improve outcomes, highlighting the need for further research into effective therapies.
Area of Science:
- Pediatrics
- Nephrology
- Hematology
Background:
- Hemolytic-uremic syndrome (HUS) is a serious condition affecting infants and children.
- Effective treatments for typical childhood HUS remain a critical area of research.
Purpose of the Study:
- To evaluate the efficacy of combined heparin and dipyridamole therapy versus supportive care in childhood hemolytic-uremic syndrome.
Main Methods:
- A randomized controlled trial involving 58 infants and children with HUS.
- Patients were assigned to either heparin and dipyridamole or supportive management.
- Clinical, laboratory, renal biopsy, and long-term follow-up data were analyzed.
Main Results:
- No significant difference in overall illness evolution between groups.
- The treated group showed a higher incidence of anuria.
- Faster recovery from hypertension was observed in the treated group, but long-term renal function was similar.
Conclusions:
- Heparin and dipyridamole treatment does not provide additional benefit compared to supportive therapy alone for typical childhood HUS.
- The findings suggest that current combination therapy is not superior to symptomatic management for this condition.
Abstract:
From 1976 to 1985, a total of 58 infants and children with the hemolytic-uremic syndrome were randomly assigned to treatment either with heparin and dipyridamole or with supportive management only. In the treatment group, two patients died in the early weeks of the disease. Analysis of clinical and laboratory data showed no significant difference between either group of patients as to the evolution of their illness except for a significantly higher incidence of anuria and a significantly faster recovery from hypertension in the treated group. Renal biopsy studies showed no differences between the two groups in terms of incidence and severity of the histologic lesions. The long-term data on blood pressure and creatinine clearance values in the survivors were similar in both groups. This study indicates that treatment with heparin and dipyridamole has no benefit over symptomatic therapy alone in the typical form of childhood hemolytic-uremic syndrome.